ArticleJournal of acquired immune deficiency syndromes (1999)2021
Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.
Article in Journal of acquired immune deficiency syndromes (1999), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02907944 (Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation (WHAT-IF?)
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial.Journal of addiction medicineTrial
- Clinic-wide effects of integrating substance use disorder services into HIV care: A pragmatic evaluation of early outcomes.The International journal on drug policy · 2026Article
- Healthcare Provider Perceptions on Screening and Treatment for Unhealthy Alcohol Use in HIV Primary Care Settings.AIDS and behavior · 2026Article
- Hepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation.Hepatology communications · 2025Article
- HIV treatment satisfaction: HIVTSQ-12 factor analysis and associated factors in Türkiye.BMC infectious diseases · 2024Article
- Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.Addiction science & clinical practice · 2024Review
- Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.The International journal on drug policy · 2024Article
- Harm reduction stories: leveraging graphic medicine to engage veterans in substance use services within the VA.Harm reduction journal · 2023Article
- Perspectives on contingency management for alcohol use and alcohol-associated conditions among people in care with HIV.Alcohol, clinical & experimental research · 2023Article
- Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial.Contemporary clinical trials · 2023Article
- Patient-Reported Bothersome Symptoms Attributed to Alcohol Use Among People With and Without HIV.AIDS and behavior · 2022Article
- Patients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study.Journal of substance abuse treatment · 2022Article
- Practices, attitudes, and confidence related to tobacco treatment interventions in HIV clinics: a multisite cross-sectional survey.Translational behavioral medicine · 2022Article
- The Relationship Between Drinking Behavior and Conversational Processes During a Brief Alcohol Reduction Intervention for People with HIV.AIDS and behavior · 2022Article
- Longitudinal analysis of the prevalence and correlates of heavy episodic drinking and self-reported opioid use among a national cohort of patients with HIV.Alcoholism, clinical and experimental research · 2022Article
- Optimizing Provider Preexposure Prophylaxis (PrEP) Training: A Cross-Sectional Analysis of Recommendations from Providers Across the PrEP Implementation Cascade.AIDS and behavior · 2022Article
- A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.Contemporary clinical trials · 2021Article
- Preface to special collection of articles on interventions for promoting smoking cessation among individuals with HIV.Contemporary clinical trials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWe sought to characterize readiness, barriers to, and facilitators of providing medications for addiction treatment (MAT) in HIV clinics.
settingFour HIV clinics in the northeastern United States.
methodsMixed-methods formative evaluation conducted June 2017-February 2019. Surveys assessed readiness [visual analog scale, less ready (0-<7) vs. more ready (≥7-10)]; evidence and context ratings for MAT provision; and preferred addiction treatment model. A subset (n = 37) participated in focus groups.
resultsAmong 71 survey respondents (48% prescribers), the proportion more ready to provide addiction treatment medications varied across substances [tobacco (76%), opioid (61%), and alcohol (49%) treatment medications (P values < 0.05)]. Evidence subscale scores were higher for those more ready to provide tobacco [median (interquartile range) = 4.0 (4.0, 5.0) vs. 4.0 (3.0, 4.0), P = 0.008] treatment medications, but not significantly different for opioid [5.0 (4.0, 5.0) vs. 4.0 (4.0, 5.0), P = 0.11] and alcohol [4.0 (3.0, 5.0) vs. 4.0 (3.0, 4.0), P = 0.42] treatment medications. Median context subscale scores ranged from 3.3 to 4.0 and generally did not vary by readiness status (P values > 0.05). Most favored integrating MAT into HIV care but preferred models differed across substances. Barriers to MAT included identification of treatment-eligible patients, variable experiences with MAT and perceived medication complexity, perceived need for robust behavioral services, and inconsistent availability of on-site specialists. Facilitators included knowledge of adverse health consequences of opioid and tobacco use, local champions, focus on quality improvement, and multidisciplinary teamwork.
conclusionsEfforts to implement MAT in HIV clinics should address both gaps in perspectives regarding the evidence for MAT and contextual factors and may require substance-specific models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.